logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 8 of 8 Items
Showing 1 - 8 of 8 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (8)
  • CSV
  • BibTeX
  • EndNote
  • All Results (8)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH,  et al.
2025-07-16 • Lancet Respiratory Medicine
2025-07-16 • Lancet Respiratory Medicine
Journal Article
|
Research
Journal Article
|
Letter
Journal Article
|
Research
Conference Material
|
Poster
Conference Material
|
Video

12-month post-treatment outcomes of previously treated drug-resistant tuberculosis patients subsequently treated with concomitant bedaquiline and delaminid +/- carbapenem, in Mumbai, India

Chavan V
2024-10-24 • MSF Scientific Days Asia 2024
2024-10-24 • MSF Scientific Days Asia 2024
Journal Article
|
Research
Journal Article
|
Research

Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: A multicentric retrospective cohort study

Singla R, Khan S, Silsarma A, Chavan V, Mahajan R,  et al.
2025-03-13 • Clinical Infectious Diseases
2025-03-13 • Clinical Infectious Diseases

BACKGROUND

Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. Th...

Sustained treatment success at 12 months for drug-resistant TB patients on concomitant bedaquiline-delamanid

Chavan V, Silsarma A, Mahajan R, Khan S, Singh P,  et al.
2025-02-01 • IJTLD OPEN
2025-02-01 • IJTLD OPEN

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

12-month post-treatment outcomes of previously treated drug-resistant tuberculosis patients subsequently treated with concomitant bedaquiline and delamanid +/-carbapenem, in Mumbai, India

Chavan V, Silsarma A, Khan S, Singh P, Iyer A,  et al.
2024-11-08 • MSF Scientific Days Asia 2024
2024-11-08 • MSF Scientific Days Asia 2024

Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study

Khan S, Silsarma A, Mahajan R, Davuluri P, Sutar N,  et al.
2024-10-12 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
2024-10-12 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

BACKGROUND

Tub...

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A,  et al.
2024-01-29 • medRxiv
2024-01-29 • medRxiv

BACKGROUND

Aft...